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Abstract
As in other disciplines in medicine, systematic reviews (SR) and meta-analyses (MA) in infectious diseases are an important aid to clinical
decision-making. In the present article we review features important to SRs in infectious diseases that should be addressed in most SRs and
MAs. We stress the need to include in the SR analysis all patients that were randomized; and all studies that were performed. Authors of
SRs should choose one main outcome that matters to patients, and base their conclusions mainly on this outcome. Resistance as an
outcome is a topic that should be addressed in all SRs of antibiotic treatment. Ethical aspects and especially patients’ safety should be
addressed in SRs.
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As in other disciplines in medicine systematic reviews (SR) and
meta-analyses (MA) in infectious diseases are an important aid
to clinical decision-making. In the present article we review
unique features of infectious diseases that should be addressed
in most SRs and MA. Our recommendations are based on
several assumptions that are common to all SRs and MA.
Indeed, they are the basis of evidence-based medicine. First,
rigorous methodology is needed to remove bias and provide
patients and physicians with unprejudiced recommendations.
Second, an SR should start with a protocol that deﬁnes
population, intervention, comparisons and outcome; and then
the pre-deﬁned data should be extracted from the published
studies. We should not start by asking which populations or
outcomes were addressed in the original trials; but deﬁne
them beforehand and seek for them in the results of the trials.
Third, our deﬁnitions of the population, intervention and
outcomes should stem directly from the question, does it
matter to patients?
We distinguish between SRs: the systematic collection of all
the research that was performed and that addressed a given
question, according to a deﬁned protocol; and MA: the
mathematical combination of the results of the individual
studies (usually randomized controlled trials (RCTs)).
Population
Randomized controlled trials of antibiotic agents sport a
multitude of patient groups—intent-to-treat (ITT): including all
patients that were randomized; modiﬁed ITT: all randomized
patients that were given at least one dose of the study drug;
clinical modiﬁed ITT: patients that match the disease criteria;
clinically evaluable (CE): patients that could be evaluated at the
test-of-cure day as either cure or failure; microbiologically
modiﬁed ITT: patients who were randomized and have a
microbiologically documented infection (usually susceptibility
to the test drug and the comparator is also a request); ITT
microbiologically evaluable; and the same groups according to
the treatment as actually given (per-protocol). Which should
be chosen for extraction in an SR and MA? For methodological
reasons the ITT population should be preferred [1]. It is
important to understand that groups are comparable only at
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the point of randomization, and any selection of patients after
randomization carrires the risk of nullifying the advantage of
randomization. Hence, ITT analysis is vital to avoid the
introduction of bias.
However, in an ITT analysis, patients that dropped out of
follow up are usually ‘carried forward’ in the same state as last
seen. Most of the time the last state is ‘still infected’. If the trial
aims to prove non-inferiority or equivalence rather than
superiority (as is the case for the majority of antibiotics trials) a
large number of drop-outs in both arms favours non-inferiority
or equivalence in ITT analysis, and per-protocol analysis is no
less important.
Even in infections in which microbiological documentation
seems sine qua non for diagnosis (e.g. cystitis) we should collect
data for an SR and MA on all randomized patients. For example,
in an SR and MA addressing antibiotic treatment for cystitis [2]
some studies included patients on the basis of urinary symptoms
and positive urinalysis, before the results of urine culture were
available. In some patients urine cultures were negative. We
would like to know whether one treatment is better than
another in these patients (with a negative culture) as well. The
data on all patients answer the question that matters to patients:
in a woman with urinary symptoms and leucocyturia, managed
according to clinical practice (i.e. given antibiotics before the
results of the culture are known), is one drug better than
another? In terms of efﬁcacy and mechanisms of action, the
women with positive culture are of interest. Hence, we should
collect and report data on all the randomized patients; on those
with negative cultures and on those with a positive culture (and
preferably also separate those with susceptible isolates from
those with resistant isolates).
Intervention and Comparison
Systematic reviews can ask general questions about interven-
tions; e.g. are b-lactam/aminoglycoside combinations better
than a single b-lactam drug [3,4]? In cancer patients on
chemotherapy, is prophylaxis with anti-fungal drugs that have
anti-mould activity better than with drugs that do not have
such activity [5]? These general questions are helpful for
managing patients: their results can be translated into practice
recommendations at speciﬁc locations, according to local
pathogens, susceptibilities and customs.
We should address interventions that are relevant to clinical
practice. Probably we would not consider treatment with
ﬂuoroquinolones for patients with skin and soft-tissue infections
who are at low risk for gram-negative pathogens. Yet because of
regulatory requirements such studies are carried out [6–8].
Similarly, guidelines do not recommend vancomycin plus
aztreonam [9] for treatment of skin and soft-tissue infections,
nor is it a combination in daily use, yet it is used as a comparator
in RCTs of skin and soft-tissue infections. We doubt whether
the inclusion of such comparisons in SRs is of use.
Outcomes
The choice of outcomes in SRs was addressed in depth in
another review [10]. In short, the outcomes should matter to
patients and should be chosen speciﬁcally for the SR. Many times
outcomes that are chosen in RCTs are problematic. They are
chosen to limit the sample size, andwemight suspect sometimes
that they are chosen because they are easier to manipulate. For
example, a change in antibiotic treatment is less important to
patients if the outcome is otherwise benign. Choosing such an
outcome might bias in favour of newer, trendier antibiotics. (In
an unblinded study, when in doubt whether the patient is
responding, a physician might be more likely to stop an old
medication rather than a new ‘wonder’ drug.)
For SRs of infections that might end in death, fatality rate
should be the main outcome. Then we should count major
complications (e.g. the need for tracheal intubation, haemodial-
ysis, operation, severe adverse events, or admission to an
intensive care unit). A timely return to the former functional
trajectory and a short hospital stay are important to most
patients. Severe infections have long-term consequences [11].
Randomized controlled trials do not plan for long-term follow up;
however, the decision to look for long-term consequences in SRs
might make a difference for the planning of future trials as well.
The question of the main outcome might be more compli-
cated in less severe infections. What matters to people with
simple cystitis? Certainly, clinical improvement or cure rather
than bacteriological eradication. But how to quantify clinical
cure? Is it the duration of symptoms that matters, or the
duration of severe symptoms?Which urinary symptoms matter
most? We doubt that ‘cure at 7 days’ or ‘cure at 30 days’ really
capture the outcomes that are important to patients. Probably
we should ask the patients about their perceptions.
The choice of one main outcome that matters to patients
should be emphasized. The conclusions of the review should
be based mainly on this outcome. This is to prevent the
situation in which conclusions in favour of an intervention are
based on one of many secondary outcomes.
Induction of Resistance
Antibiotics are a non-renewable resource. Use of antibiotics
induces resistance and limits our anti-infective arsenal for the
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future. If an intervention could inﬂuence resistance it is
important to document this inﬂuence. Most SRs include only
RCTs, and the time-frames of RCTs are not compatible with
the time-frame of development of resistance in a unit or
hospital. Nevertheless, data on acquisition of resistance by
pathogens, super-infections caused by resistant pathogens, or
colonization with resistant bacteria often exist and should be
collected [12].
Inclusion of Observational Studies
Most SRs and MA include only RCTs. In MA of RCTs we
combine an effect size (e.g. relative risk). We do this because
the randomization allows us to assume that any differences
between the arms of a study, but for the effect of the
intervention, are due to chance.This assumption does not hold
true in observational studies, and combination of observational
studies in MA is problematic. However, there are instances in
which we want to look at observational studies, and even
combine their results using MA; e.g. comparisons in which an
RCT would be unethical; or questions for which few or no
RCTs were performed and the chances of obtaining results
from an RCT in the near future are non-existent. For example,
the question of whether appropriate, early, empirical antibiotic
treatment has a beneﬁt cannot be addressed directly through
an RCT but many observational studies were performed with
this question in mind and their results are important when
deciding on the broadness of empirical antibiotic treatment
[13].
Completeness of the Database
A problem common to all SRs is obtaining the complete results
of all the trials that were performed. Mandatory registration of
trials might solve this problem; but we are not there yet.
Infectious diseases offer quite a few disturbing examples: a
Cochrane review could not reach strong conclusions on the
effectiveness of oseltamivir because the authors were denied
access to the full data on unpublished trials [14]. We were
surprised to ﬁnd that 27 trials comparing cefepime with
another antibiotic were not published; and could not ascertain
the design and full data of these trials [15,16]. Withholding data
raises a strong suspicion of bias and manipulation. We should
remember that the main investment in RCTs is the goodwill
and efforts of the participants and researchers, and not the
money of the sponsor. This creates an ethical commitment to
publish every trial in full.
Ethics
We have proposed a framework for including in SRs informa-
tion on the ethical aspects of studies [17]. We had a clear
impression that reports with possible ethical ﬂaws also had
weaker methodology.
Safety of included patients is probably the most important
ethical aspect. For example, we have shown that in some
clinical trials of antibiotic treatment the in vitro susceptibility of
pathogens to the study drugs was not disclosed to the
attending physicians in real time, even for septic patients [18].
Summary
In conclusion, we stress the need to include in the SRs and MA
all patients that were randomized; and all studies that were
performed. Authors of SRs should choose one main outcome
that matters to patients, and base their conclusions mainly on
this outcome. Resistance as an outcome is a topic that should
be addressed in all SRs of antibiotic treatment. Ethical aspects
and especially patient safety should be addressed in SRs.
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